Jounce’s drug, called JTX-2011, helps stimulate the immune system to fight off cancer. The company is targeting biological markers on tumors, hoping to provide more specific, individualized therapy matches for patients.
The Cambridge, Mass.-based company will receive $225 million upfront from Celgene for an option to jointly develop JTX-2011, among other new treatments. Additionally, Celgene will invest $36 million in Jounce for a minority stake.
Jounce, which was founded three years ago and only has 60 employees, could earn up to $2.3 billion in further milestone payments.
The company expects to start clinical trials for JTX-2011 later this year.
More articles on the drug market:
FDA approves Aurobindo’s new pain med
Roche’s blood cancer drug disappoints in clinical trial
PhRMA adds 5 new companies to its ranks, including generic rival Teva
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
